To quantify changes over time in cardiovascular (CV) risk factor control and in the uptake of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors from 2007 to 2020… Click to show full abstract
To quantify changes over time in cardiovascular (CV) risk factor control and in the uptake of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors from 2007 to 2020 in a real‐world community‐based cohort of type 2 diabetes (T2D) patients.
               
Click one of the above tabs to view related content.